Mazdutide Research for Non-Alcoholic Fatty Liver Disease
An evidence-based overview of research examining Mazdutide in the context of non-alcoholic fatty liver disease. This page synthesizes findings from peer-reviewed literature.
Research Summary
Mazdutide's glucagon receptor activation is proposed to reduce hepatic fat via increased fatty acid oxidation. GLORY-1 reported beneficial effects on all prespecified cardiometabolic measures, and reviews of GLP-1/glucagon dual agonists note potential to ameliorate fatty liver disease. Dedicated MRI-PDFF liver-fat outcome data for mazdutide are not yet published.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Mazdutide may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.